Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Supervisory Board
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • ANKET®: Our NK cell engager Platform
    • Publications
  • Products
    • Pipeline overview
    • Clinical trials
    • ------------------
    • IPH6501
    • IPH6101
    • IPH6401
    • IPH62
    • IPH4502
    • Lacutamab
    • Monalizumab
    • IPH5201
    • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

Pipeline overview

  1. Home
  2. Products
IPH6501
CD20, 2nd generation ANKET®

Cancer

Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
IPH6101 (SAR'579)
CD123, trifunctional ANKET®
Partnered with Sanofi

Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High Risk-myelodysplasia

Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
IPH6401 (SAR'514)
BCMA, trifunctional ANKET®
Partnered with Sanofi

Multiple Myeloma

Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
IPH62
B7-H3, multi-specific ANKET®
Partnered with Sanofi

Cancer

Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
IPH67
undisclosed, multi-specific ANKET®

Cancer

Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
IPH4502
Nectin-4, Antibody Drug Conjugate
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
IPH43
MICA/B, Antibody Drug Conjugate
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Lacutamab
KIR3DL2
Proprietary program

Cutaneous T Cell Lymphoma (Sézary Syndrome / Mycosis Fungoides)

Phase 2
Preclinical
Phase 1
Phase 2
Phase 3

Peripheral T Cell Lymphoma

Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Monalizumab
NKG2A
Co-development with AstraZeneca

Unresectable Stage III Non-small Cell Lung Cancer

Phase 3
Preclinical
Phase 1
Phase 2
Phase 3

Neoadjuvant NSCLC, other

Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
IPH5201
CD39
Partnered with AstraZeneca

Neoadjuvant Non-small Cell Lung Cancer

Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
IPH5301
CD73
Proprietary program

Cancer (Solid Tumors)

Phase 1
Preclinical
Phase 1
Phase 2
Phase 3

Footer

  • Contact
  • Location
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

 +33 (0)4 30 30 30 30

 Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Supervisory Board
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • ANKET®: Our NK cell engager Platform
    • Publications
  • Products
    • Pipeline overview
    • Clinical trials
    • ------------------
    • IPH6501
    • IPH6101
    • IPH6401
    • IPH62
    • IPH4502
    • Lacutamab
    • Monalizumab
    • IPH5201
    • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers